Protea Biosciences Group (PRGBQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2011 | |
| Cash Flows From Operating Activities | |
| Net Income | -11,497 |
| Depreciation Amortization | 1,280 |
| Accounts receivable | -26 |
| Accounts payable and accrued liabilities | 781 |
| Other Working Capital | 1,508 |
| Other Operating Activity | -12 |
| Operating Cash Flow | $-7,967 |
| Cash Flows From Investing Activities | |
| PPE Investments | -1,242 |
| Investing Cash Flow | $-1,242 |
| Cash Flows From Financing Activities | |
| Change In Short Term Borrowing | 7,405 |
| Debt Repayment | -402 |
| Common Stock Issued | 2,282 |
| Financing Cash Flow | $9,285 |
| Exchange Rate Effect | 19 |
| Beginning Cash Position | 411 |
| End Cash Position | 505 |
| Net Cash Flow | $95 |
| Free Cash Flow | |
| Operating Cash Flow | -7,967 |
| Capital Expenditure | -1,242 |
| Free Cash Flow | -9,209 |